Wanxing Cui MD, PhD, CABP(H)

Dr. Wanxing Cui is the Director of the Cell Therapy Manufacturing Facility at MedStar Georgetown University Hospital, where he oversees an FDA-registered operation adhering to standards set by the AABB, CAP, and FACT. With over 27 years of experience in pancreatic islet transplantation, he has significantly contributed to the Pancreatic Islets and Stem Cell Transplant and Cellular Immunotherapy programs at the hospital. Dr. Cui earned his Ph.D. in Molecular Medicine from Kyoto University, Japan, focusing on developing a bioartificial pancreas. He has authored over 70 peer-reviewed publications and holds several biotechnological patents. An active AABB assessor and FACT inspector, he contributes to advancing cell therapy standards. Additionally, he participates in the ISCT's iPSC Joint and Lab Practice Committees and serves as a mentor in ISCT's Professional Education Program (PEP) and AABB's Early Stage Professionals (ESP) programs. Dr. Cui is also a member of the AABB Cellular Therapies Section Coordinating Committee (CTSCC), furthering advancements in cell therapy.